Skip to main content
LDOS logo

LDOS · Leidos Holdings, Inc.

Track LDOS — free
$130.02 -0.51 (-0.39%) At close · Nov 16
Market Cap
$15.86B
Shares
121.99M
Volume · Nov 16 751.36K Avg daily vol (3M) 1.15M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$130.02 Open$132.00 Day$129.55–133.05 52W close$100.00–198.34 Avg vol 30d1.1M Short int3.9M · 3.2% of shares · 4.5d Short vol45% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Oct 2
Revenue rises while backlog reaches $49,554 million

Leidos reported three-month revenues of $4,630 million and net income of $413 million for October 2, 2026, while total backlog reached $49,554 million. Cash was $630 million and debt $6.0 billion.

Revenue $4.63B ▲ 3.6% Net income $410M ▲ 11.7% Diluted EPS $3.28 ▲ 16.3%
Read from the MD&A section
6 source passages
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Revenues | 4,630 | | | 4,469 | | 3.6% | 13,588 | | 12,967 | | 4.8% Net income | 413 | | | 369 | | 11.9% | 1,104 | | 1,127 | | (2.0%) Total | 11,062 | 38,492 | 49,554 | 9,064 | 38,592 | 47,656 As of October 2, 2026, we had $630 million in cash and cash equivalents. We had outstanding debt of $6.0 billion and $4.6 billion at October 2, 2026, and January 2, 2026, respectively. Open the document at this passage
Nov 3
Current report 8-K
Third-quarter growth raises EPS guidance despite revenue reduction

Leidos generated $4.63 billion revenue, up 4%, and $413 million net income in the third quarter. Full-year revenue guidance was reduced to $18.00 - $18.20, while non-GAAP diluted EPS guidance increased to $12.50 - $12.70.

Financial results
5 source passages
Leidos Holdings, Inc. (NYSE: LDOS) today reported financial results for the third quarter of fiscal year 2026, highlighted by robust revenue growth and free cash flow generation. Revenues for the quarter were $4.63 billion, up 4% compared to the third quarter of 2025. For the third quarter, net income was $413 million, or $3.28 per diluted share. Revenues (B) | $18.00 - $18.20 | $18.20 - $18.40 Non-GAAP Diluted EPS | $12.50 - $12.70 | $12.20 - $12.50 Open the document at this passage
Nov 3
Earnings call
Leidos enhances 2026 guidance after 19% EPS growth

Leidos reported third-quarter revenue of $4.63 billion, up 4%, non-GAAP diluted EPS of $3.62, up 19% year-over-year, and $476 million of free cash flow. It enhanced 2026 guidance, while VBA contract changes drove Health contraction.

6 source passages
I'm glad you could join us on this U.S. Election Day to review another strong quarter at Leidos. Revenue for the quarter was $4.63 billion, up 4% in total and 1% organically year over year. Non-GAAP diluted EPS grew 19% year-over-year to $3.62. In the quarter, we generated $523 million of cash flows from operating activities and $476 million of free cash flow. This performance allows us to, once again, enhance our 2026 guidance for the year. And health segment contraction was driven by the VBA business for the reasons we previously outlined. Open the document at this passage
Oct 5
Current report 8-K
Entered into a material agreement, Regulation FD disclosure

Leidos Holdings, Inc. closed the Nickel JV Ultimate Parent, LLC transaction on October 5, 2026, contributing the SES/IA Business for 41.5% equity while AHP Entities received 58.5%; the AHP Investor will appoint a majority of the board.

Read from the first part of this long document
Oct 1
Current report 8-K
Director or officer change, or executive pay

Leidos Holdings, Inc. elected Jeffery S. McElfresh to its board effective October 1, 2026, increasing the board to 11 members and assigning him to the Corporate Governance and Ethics and Technology and Information Security Committees.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$17.80B
Trailing 12 months
Net income (TTM)
$1.42B
Trailing 12 months
Revenue growth YoY
+3.6%
Year over year
Operating margin
11.5%
Trailing 12 months
P / E (TTM)
11.7
Trailing earnings · reciprocal yield 8.6%
FCF yield
12.3%
TTM · current market cap
Return on invested capital
15.6%
Trailing 12 months
Net cash
−$5.40B
Latest balance sheet
Dividend yield
1.3%
Trailing 12 months
Shares change YoY
-3.8%
Year over year · fewer shares
Price change (1Y)
-31.8%
Trailing year
Short interest
3.2%
Latest settlement · 4.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Leidos delivered 4% revenue growth, 19% non-GAAP EPS growth, higher adjusted EBITDA margin, 22% funded-backlog growth, higher EPS and operating-cash-flow guidance, and major new bookings and awards. Offsetting those gains, revenue guidance was lowered, Health revenue, margins and backlog weakened, cash generation declined, interest expense increased, nine-month operating results weakened, organic growth was only 0.6%, and transaction costs affected results.

Bullish
  • + Revenue increased 4% year over year to $4.63 billion.
  • + Non-GAAP diluted EPS increased 19% year over year to $3.62.
  • + Adjusted EBITDA increased 5% year over year to $644 million, while margin improved to 13.9% from 13.8%.
  • + Funded backlog increased 22% year over year to $11.1 billion.
Bearish
  • − Strategic corporate transactions resulted in $12 million of costs in the quarter.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg +1%
above
RSI (14) 45
neutral
MACD trend Negative
52-week position 31%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +3%
trailing
6-month return 0%
trailing
YTD return −28%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $129 › 200d $138 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +122 funds added
Insider flow Distributing
Net -$140.8K over 90 days · 100% sells
Short interest Falling
3.20% of shares out · ▼ -10.2% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
727 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
Revenue growth +3%
Y/Y
EPS growth +21%
Y/Y
Free cash flow $1.6B
Valuation P/E 11.6
below peers
Balance sheet $3.5B
net debt
Quant / Vol
risk profile
High
Volatility 36%
annualized · 1-yr
Max drawdown −50%
past year
ATR 3.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the Earnings Call filed Nov 3, 2026
the fourth quarter
SES revenue $200M
Q4
Q4 cash projection $20M
Transaction costs $30M
2026
Non-GAAP effective tax rate Non-GAAP 20%
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA Margin · fiscal year 2026 13%
Non-GAAP Diluted EPS · fiscal year 2026 $12.20 – $12.50
Prior guidance period ended · from the Earnings Call filed Nov 3, 2026
Non-GAAP diluted EPS · 2025 $11.45 – $11.75
Operating cash flow guidance · 2025 $1.65B
Revenue guidance · 2025 $17B – $17.25B
Guided vs delivered · last 2 settled
2022 revenues 2022
guided $14.2B – $14.4B
$14.4B In line
Revenues fiscal year 2021
guided $13.7B – $13.9B
$13.74B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
+1% Bullish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
31% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $129 › 200d $138 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +122 funds added
Insider flow Distributing
Net -$140.8K over 90 days · 100% sells
Short interest Falling
3.20% of shares out · ▼ -10.2% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
727 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $100 Now $130 · 31% Range high $198
vs 200-day avg -6% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $1.25B Six Months Ended July 3, 2026 -0.2%
Adjusted EBITDA margin non-GAAP 13.9% Six Months Ended July 3, 2026 -5.4%
Book-to-bill ratio 1.1 Q2 FY2026 —
Defense backlog $13.76B July 3, 2026 —
Defense non-GAAP operating margin non-GAAP 9.9% Three Months Ended July 3, 2026 —
Entrust backlog acquired $371M March 27, 2026 —
Free cash flow conversion ratio 185% Q2 FY2026 —
Funded backlog $10.22B As of July 3, 2026 —
Health backlog $6.61B July 3, 2026 —
Health non-GAAP operating margin non-GAAP 23.8% Three Months Ended July 3, 2026 —
Homeland backlog $9.93B July 3, 2026 —
Homeland non-GAAP operating margin non-GAAP 12.1% Three Months Ended July 3, 2026 —
Intelligence & Digital backlog $18.41B July 3, 2026 —
Intelligence & Digital non-GAAP operating margin non-GAAP 10.1% Three Months Ended July 3, 2026 —
Net bookings 4.9B Q2 FY2026 —
Non-GAAP Diluted Earnings per Share non-GAAP $3.26 Q2 FY2026 —
Non-GAAP diluted EPS non-GAAP $6.39 Six Months Ended July 3, 2026 —
Non-GAAP Free Cash Flow non-GAAP 761M Q2 FY2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities 793M
-32M Payments for property, equipment and software
= Non-GAAP free cash flow 761M
Non-GAAP net income attributable to Leidos common stockholders non-GAAP $411M Three Months Ended July 3, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income attributable to Leidos common stockholders 354M
+26M Acquisition, integration and restructuring costs
+30M Amortization of acquired intangibles
+1M Asset impairment charges
= Non-GAAP net income attributable to Leidos common stockholders 411M
Non-GAAP operating income non-GAAP $1.16B Six Months Ended July 3, 2026 —
Non-GAAP operating margin non-GAAP 12.9% Six Months Ended July 3, 2026 —
Operating cash flow conversion ratio 224% Q2 FY2026 —
Total backlog $48.71B As of July 3, 2026 —
Trailing-twelve-month book-to-bill 1.1 Q2 FY2026 —
Unfunded backlog $38.49B As of July 3, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Information Technology Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LDOS
Leidos Holdings, Inc.
this stock
$15.86B -27.9% +3.1% 11.6 3.2%
IBM
International Business Machines Corp
$229.20B -18.1% +7.6% 20.6 1.9%
ACN
Accenture plc
$165.72B -7.7% +6.5% 18.3 3.2%
INFY
Infosys Ltd
$49.86B -30.9% — — 2.1%
CTSH
Cognizant Technology Solutions Corp
$27.85B -25.0% +7.0% 11.4 5.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
727
% held
73.2%
Net QoQ
-10.7M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
738
View
Short & Settlement
Short Interest Falling
Shares short
3.9M
Days to cover
4.5d
Change
-443.5K sh
View
Short Volume
Short vol %
45%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$698
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
37.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$140.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Alan Armstrong
Amount
$15.0K–$50.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$17.2B
Net income (FY)
$1.4B
EPS diluted
$11.14
View
Buybacks
Authorized
shares 40.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
21

Leidos reported three-month revenues of $4,630 million and net income of $413 million for October 2, 2026, while total backlog reached $49,554 million. Cash was $630 million and debt $6.0 billion.

View
Proposed Sales
Value
$140.8K
Shares
1.0K
Filed
Sep 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Leidos introduces HeadWay Dispatc…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
LDOS -4.2% +3.2% -0.5% -9.1% -27.9%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -2.5% +6.6% +0.9% -7.0% -36.4%

Capital returns

Latest dividend
$0.43 / share · ex Sep 15, 2026
Declared · upcoming
$0.45 / share · ex Dec 15, 2026
Raised 7.5%
Paid (TTM)
$1.72 / share · 4 payouts
Dividend yield (TTM, derived)
1.32%
Full dividend history
Buyback program · as of Jan 31, 2012
Authorized
shares 40.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1336920 CUSIP 525327102 13F (30d) 694 filings 653 filers Visit website Investor relations